Popular

Exploring Innovations in Colorectal Cancer Screening: Liquid Biopsy and Beyond
WHO Revises Catalog of Drug-Resistant Bacteria Posing Greatest Human Health Risks
FDA Grants Approval for IMDELLTRA™ (Tarlatamab-dlle): First T-cell Engager Therapy for Extensive-Stage Small Cell Lung Cancer
Merck to Unveil Latest Findings at 2024 ASCO Annual Meeting Showcasing Progress in Innovative Oncology Treatments Across Extensive Portfolio and Varied Pipeline

What is CAR-T cell therapy?

CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is a revolutionary form ofimmunotherapy that has gained significant attention in recent years for its remarkable success intreating certain types of cancer, particularly blood cancers. This cutting-edge treatment involvesharnessing the power of the patient’s immune system to target and destroy cancer cells, offeringnew hope for…

Read More

Crucible Therapeutics, a spinout of the University of Sheffield in England, has secured £5million (approximately $6.1 million) in funding to advance its development of genetherapies

Gene therapies will be targeting neurodegenerative disorders associated with C9orf72gene mutations. The financing comes from investment firm Northern Gritstone and Europeanstartup studio Argobio Studio. These funds will support preclinical development andmanufacturing efforts aimed at preparing Crucible Therapeutics for its initial clinical trial. Thecompany’s focus is on addressing conditions such as motor neuron disease (MND), amyotrophiclateral…

Read More

Navigate BioPharma, a subsidiary of Novartis, has recently announced a strategic collaboration with Becton Dickinson (BD)

Collaboration aimed at advancing the development and commercialization of companion diagnostics and clinical decision-making tools utilizing flow cytometry technology. This partnership represents a significant step in the field of precisionmedicine and holds the potential to enhance the efficiency and accuracy of patient treatmentmatching.Through this collaborative effort, BD and Navigate BioPharma aim to offer comprehensivesolutions for…

Read More

AstraZeneca and Daiichi’s breast cancer drug Shows Promise in Phase III BreastCancer Trial

AstraZeneca’s Dato-DXd, an antibody drug conjugate, has shown promising results in a Phase IIIbreast cancer trial, known as TROPION-Breast01, conducted to assess its effectiveness inpatients with advanced HR-positive, HER2-low or -negative breast cancer. The trial revealed asignificant and clinically meaningful improvement in progression-free survival when comparedto chemotherapy chosen by investigators. AstraZeneca intends to share these…

Read More

Exploring Innovations in Colorectal Cancer Screening: Liquid Biopsy and Beyond

Colorectal cancer (CRC) remains a significant global health challenge due to its high incidence and mortality rates. Despite advancements in treatment, identifying patients who could benefit from specific therapies remains challenging. Traditional tissue biopsies have limitations such as spatial and temporal heterogeneity. Liquid biopsy (LB), particularly circulating tumor DNA (ctDNA) analysis, emerges as a promising…

Read More

WHO Revises Catalog of Drug-Resistant Bacteria Posing Greatest Human Health Risks

The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, spotlighting 15 families of antibiotic-resistant bacteria classified into critical, high, and medium priority categories. This initiative aims to steer research and development efforts towards combating antimicrobial resistance (AMR), a global health crisis exacerbated by the misuse of antibiotics. Critical…

Read More

FDA Grants Approval for IMDELLTRA™ (Tarlatamab-dlle): First T-cell Engager Therapy for Extensive-Stage Small Cell Lung Cancer

Amgen’s IMDELLTRA™ (tarlatamab-dlle) has gained FDA approval for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) post platinum-based chemotherapy progression. This milestone reflects a significant advancement, offering hope to a patient population with limited treatment options. The approval is based on compelling data from the Phase 2 DeLLphi-301 trial, showcasing IMDELLTRA’s efficacy in…

Read More

Merck to Unveil Latest Findings at 2024 ASCO Annual Meeting Showcasing Progress in Innovative Oncology Treatments Across Extensive Portfolio and Varied Pipeline

Merck, also known as MSD outside the United States and Canada, is set to unveil a wealth of data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, spanning various oncology medicines and pipeline candidates targeting over 25 types of cancer. These presentations highlight Merck’s ongoing commitment to advancing cancer research…

Read More

Diasorin Secures FDA 510(k) Clearance for Enhanced Respiratory Panel

Diasorin recently announced that the US Food and Drug Administration has granted 510(k) marketing clearance for their updated molecular respiratory panel, now including SARS-CoV-2 detection. The NxTag Respiratory Pathogen Panel v2, based in Saluggia, Italy, utilizes multiplex PCR to identify 19 viral and two bacterial targets in nasopharyngeal swab samples from patients displaying respiratory symptoms….

Read More

Seegene and Springer Nature Forge Strategic Partnership

Seegene , a leading South Korean PCR molecular diagnostics company, has entered a strategic alliance with Springer Nature, publisher of the prestigious journal, Nature. Aligned in their mission to advance scientific discovery and combat diseases, this alliance aims to accelerate PCR diagnostic testing across various disease areas. The collaboration leverages the expertise of both parties…

Read More

Radiation oncology in the era of Precision Medicine

Radiation therapy utilizes high doses of ionizing or particulate radiation to kill cancer cells. It is an integral component of multimodality cancer care. However, the challenge lies in delivering it precisely to the target while sparing surrounding healthy tissues. Technological advancements have revolutionised radiation therapy planning and delivery leaps and bounds. Especially incorporation of axial…

Read More

U.S. FDA Grants Approval to Bristol Myers Squibb’s Breyanzi CAR T Cell Therapy for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CAR T cell therapy targeting CD19, to treat adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone two or more prior lines of systemic therapy. This approval, based on response rate…

Read More

Indian Council of Medical Research (ICMR) Issues Protocol for Evaluating TB Detection Technologies: A Generic Concordance Study

The Indian Council of Medical Research (ICMR) has issued a Generic Concordance Study Protocol aimed at evaluating tuberculosis (TB) detection technologies. This protocol seeks to establish the agreement between two iterations of an approved molecular TB detection technology. Through a cross-sectional approach, it aims to ascertain the concordance in identifying both TB and drug-resistant TB…

Read More

Bayer Initiates Phase I Trial of Innovative Targeted Radionuclide Therapy, 225Ac-PSMA-Trillium, in Advanced Metastatic Prostate Cancer

Bayer has announced the commencement of dosing in a Phase I clinical study for 225Ac-PSMA-Trillium (BAY 3563254), a novel targeted alpha therapy aimed at treating advanced metastatic castration-resistant prostate cancer (mCRPC). This investigational candidate, utilizing actinium-225, features a unique PSMA-targeting small molecule with a customized albumin-binding component. The study, identified as NCT06217822, will focus on…

Read More